Nikang Therapeutics

NiKang Therapeutics develops small molecules for oncology. Its lead HIF2A inhibitor targets kidney cancer, aiming for clinical advancement.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series C
Initial Investment Year
2021